Artimplant year-end results, January 1 - December 31 2002

ARTIMPLANT's year-end results, January 1 - December 31 2002 RESTRUCTURING COMPLETED FOCUS ON COMMERCIALIZATION - Artimplant issued 10 million shares in a directed issue to existing and new institutional stockholders and owners with larger stock holdings. The issue injected SEK 30 million into the company. - In the next step, the company plans to raise at least SEK 15 million through a preferential rights issue in late March 2003. - Tord Lendau became the new CEO on October 3. - Following the new strategy the total cost of the parent company is reduced by 40 percent. The action program leads to a considerable reduction in the operative cash burn that is estimated to amount to around SEK 35 million in 2003. - Preparations were launched for the sale of Gothenburg Medical Center (GMC), a subsidiary. - Group sales increased 8% to SEK 25.7 million (23.7). Operating loss was SEK 63 million (58.2). Loss increased primarily because of restructuring and settlements with personnel. Restructuring cost was SEK 6.2 million. Forthcoming financial reports: Annual General Meeting: April 29, 2003, 5 p.m. 1Q 2003 report: April 30, 2003 January-June 2003 report: August 29, 2003 January-September 2003 report: November 7, 2003 Financial reports are available at www.artimplant.se at the same time that they're distributed to the media. For more information, contact: Tord Lendau, CEO, +46 708 369 403, tord.lendau@artimplant.se Ulf Åkerblom, investor relations, +46 709 675 999, ulf.akerblom@artimplant.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/02/14/20030214BIT00360/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/02/14/20030214BIT00360/wkr0002.pdf The full report